Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 2/20 | 0.35 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1768213 | 1.00 | CXCR2 (0.35) | CXCR2CXCR1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL1924669 | 1.00 | CXCR2 (0.35) | CXCR2CXCR1TP53ALDH1A1L3MBTL1 | |
| SCHEMBL16186409 | 0.84 | CXCR2 (0.34) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL10198565 | 0.84 | CXCR2 (0.34) | CXCR2CXCR1ALDH1A1L3MBTL1 | |
| SCHEMBL2598240 | 0.81 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL16584183 | 0.81 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL2797628 | 0.81 | CA14 (0.41) | CXCR2CXCR1 | |
| SCHEMBL3756194 | 0.81 | CA2 (0.41) | — | |
| SCHEMBL3756191 | 0.81 | CA2 (0.41) | — | |
| SCHEMBL575704 | 0.80 | CA1 (0.33) | CXCR2CXCR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2771340-B1 | 6-(4-HYDROXY-PHENYL)-1H-PYRAZOLO[3,4-B]PYRIDINE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS KINASE INHIBITORS | SANOFI SA (FR) | 2016-04-13 | — | — | EP | claimed |
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | SANOFI (FR) | 2013-06-13 | — | — | US | claimed |
| CN-117693502-A | Compounds for inhibiting or degrading ITK, compositions comprising the same, methods of making the same, and methods of using the same | 纽力克斯治疗公司 | 2024-03-12 | — | — | CN | disclosed |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
| CN-117120418-A | Process for the preparation of compound (I) | 百时美施贵宝公司 | 2023-11-24 | — | — | CN | disclosed |
| EP-4225757-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | Bristol-Myers Squibb Company (US) | 2023-08-16 | — | — | EP | disclosed |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-11608323-B2 | Herbicidal compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2023-03-21 | — | — | US | disclosed |
| US-11491245-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2022-11-08 | — | — | US | disclosed |
| WO-2022081473-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3054773-B1 | HERBICIDAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2022-01-26 | — | — | EP | disclosed |
| US-6403580-B1 | HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES, THE USE THEREOF FOR TREATING DISEASES, PARTICULARLY TUMORAL DISEASES, DISEASES OF THE LUNGS AND RESPIRATORY TRACT, AND THE PREPARATION THEREOF. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-06-11 | — | — | US | disclosed |
| EP-0850246-B1 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2001-11-14 | — | — | EP | disclosed |
| US-5973188-A | Acetic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 1999-10-26 | — | — | US | disclosed |
| EP-0850247-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| EP-0850246-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-07-01 | — | — | EP | disclosed |
| US-5705492-A | ESTERIFICATION OF PYRIMIDINE NUCLEOSIDE | HOFFMANN-LA ROCHE INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5698532-A | VIRICIDE THAT FUNCTIONS AS A THYMIDINE KINASE ENZYME INHIBITOR FOR TREATMENT OR PROPHYLAXIS OF HERPES SIMPLEX VIRUS; ENHANCED BIOAVAILABILITY | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | disclosed |
| WO-1997003082-A2 | PYRIMIDINE NUCLEOSIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-30 | — | — | WO | disclosed |
| WO-1997003083-A1 | PYRIMIDINE NUCLEOSIDE DERIVATIVE | F. HOFFMANN-LA ROCHE AG (CH) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11491245-B2 | Gadolinium chelate compounds for use in magnetic resonance imaging | GLRA1, GLRA3, GLRB | CXCR2 2191/4885CXCR1 987/4885TP53 2459/4885 |
| US-20130150340-A1 | 6-(4-Hydroxy-phenyl)-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors | MAP3K1, MAP4K2, MAP3K19 | CXCR2 1614/4885CXCR1 1567/4885TP53 3265/4885 |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | CYP1B1, AZI2, TET1 | CXCR2 1626/4885CXCR1 401/4885TP53 4478/4885 |
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | CXCR2 4170/4885CXCR1 4732/4885TP53 128/4885 |
| US-11608323-B2 | Herbicidal compounds | DDT, RDX, CBR3 | CXCR2 1377/4885CXCR1 750/4885TP53 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.